ClinicalTrials.gg
Active, not recruitingNCT03191656REDUCELAPHFIIIUpdated May 12, 2026

REDUCE LAP-HF III Corvia Protocol 1701

An observational study in Heart Failure, sponsored by Corvia Medical. Active, not recruiting at 27 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Corvia Medical · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
500
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 600 studies in Heart Failure with a site in Germany — 105 open to participants now, 136 under way, 19 of them phase 3. Heart Failure · Germany.

Planned enrollment
75th of 212
500 · median 286
Started
2017
with 43 others
Observational
212 of 600
47 open now
Primary completion
2026-07
later than 38 of 135 live
Registered
344th of 600
by date

Among the 600 studies in Heart Failure with a site in Germany, this one is the 75th largest by planned enrollment of the 212 observational ones that give a count, is one of 44 that started in 2017, is one of 212 observational ones, reaches primary completion later than 38 of the 135 other live ones, and was the 344th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

105 of the 600 studies in Heart Failure with a site in Germany are open now. Recruiting first, the newest first:

100 more — sign in →

All 105 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Heart Failure with a site in Germany, or all of them as a file.
02

Study summary

This is a post market trial to be conducted at sites in Germany. The device has CE approval in the EU. The purpose of this observational registry is to collect post market data in consecutive patients treated with the IASD System II, to further evaluate efficacy, safety and quality of life outcomes as a new treatment for patients with heart failure in a "real world" practice setting.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with heart failure with preserved (HFpEF) or mid-range ejection fraction (HFmrEF) with elevated left atrial pressures, who remain symptomatic despite standard Guideline Directed Medical Therapy (GDMT), in accordance with CE-mark approved labeling.

Eligibility criteria

This is a post market registry so no criteria requirements (only recommendations).

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Interventions

  • DeviceIASD Implant

    Implantation of the IASD device using trans-septal puncture and the IASD system

06

What researchers measure

Primary outcomes

  1. Serious Adverse Events

    Device and or procedure related serious adverse cardiac events

    Time frame: 30 days

  2. New York Heart Classification

    Improvement in NYHA Classification

    Time frame: 12 months

  3. Quality of Life Improvement (KCCQ score)

    Improvement in KCCQ score

    Time frame: 12 months

  4. Quality of Life Improvement (EQ5D)

    Improvement in EQ5D score

    Time frame: 12 months

07

Study locations

27 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2017 (actual). Primary completion is estimated for Jul 2026, 112 months after the start.

Of 183 industry-sponsored observational studies under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 57. This study's planned 112 months is above that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2017
First posted
Jun 19, 2017
StartActual
Mar 12, 2017
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jul 31, 2028
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03191656
Lead sponsor
Corvia Medical
Responsible party
Sponsor
First posted
Jun 19, 2017
Start date
Mar 12, 2017
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
May 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion